Amy C Porter1, Jiri Aubrecht2, Chandler Birch1, Jonathan Braun3, Carolyn Cuff4, Suryasarathi Dasgupta2, Jeremy D Gale5, Robert Hinton6, Steven C Hoffmann7, Gerard Honig8, Bryan Linggi9, Marco Schito1, Niels Vande Casteele10,11, John-Michael Sauer1. 1. Critical Path Institute, AZ, USA. 2. Takeda Pharmaceuticals, Cambridge, MA, USA. 3. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 4. AbbVie Bioresearch Center, Worcester, MA, USA. 5. Pfizer Worldwide, Research, Development and Medical, Cambridge, MA, USA. 6. The David R Clare and Margaret C Clare Foundation, Morristown, NJ, USA. 7. FNIH, North Bethesda, MD, USA. 8. Crohn's & Colitis Foundation, New York, NY, USA. 9. Robarts Clinical Trials, San Diego, CA, USA. 10. Department of Medicine, University of California San Diego, CA, USA. 11. Robarts Clinical Trials Inc., London, ON, Canada.
Abstract
BACKGROUND: Currently, 2 coprimary end points are used by health authorities to determine the effectiveness of therapeutic interventions in patients with Crohn's disease (CD): symptomatic remission (patient-reported outcome assessment) and endoscopic remission (ileocolonoscopy). However, there is lack of accepted biomarkers to facilitate regulatory decision-making in the development of novel therapeutics for the treatment of CD. METHODS: With support from the Helmsley Charitable Trust, Critical Path Institute formed the Crohn's Disease Biomarkers preconsortium (CDBpC) with members from the pharmaceutical industry, academia, and nonprofit organizations to evaluate the CD biomarker landscape. Biomarkers were evaluated based on biological relevance, availability of biomarker assays, and clinical validation data. RESULTS: The CDBpC identified the most critical need as pharmacodynamic/response biomarkers to monitor disease activity in response to therapeutic intervention. Fecal calprotectin (FC) and serum C-reactive protein (CRP) were identified as biomarkers ready for the regulatory qualification process. A number of exploratory biomarkers and potential panels of these biomarkers was also identified for additional development. Given the different factors involved in CD and disease progression, a combination of biomarkers, including inflammatory, tissue injury, genetic, and microbiome-associated biomarkers, will likely have the most utility. CONCLUSIONS: The primary focus of the Inflammatory Bowel Disease Regulatory Science Consortium will be development of exploratory biomarkers and the qualification of FC and CRP for IBD. The Inflammatory Bowel Disease Regulatory Science Consortium, focused on tools to support IBD drug development, will operate in the precompetitive space to share data, biological samples for biomarker testing, and assay information for novel biomarkers.
BACKGROUND: Currently, 2 coprimary end points are used by health authorities to determine the effectiveness of therapeutic interventions in patients with Crohn's disease (CD): symptomatic remission (patient-reported outcome assessment) and endoscopic remission (ileocolonoscopy). However, there is lack of accepted biomarkers to facilitate regulatory decision-making in the development of novel therapeutics for the treatment of CD. METHODS: With support from the Helmsley Charitable Trust, Critical Path Institute formed the Crohn's Disease Biomarkers preconsortium (CDBpC) with members from the pharmaceutical industry, academia, and nonprofit organizations to evaluate the CD biomarker landscape. Biomarkers were evaluated based on biological relevance, availability of biomarker assays, and clinical validation data. RESULTS: The CDBpC identified the most critical need as pharmacodynamic/response biomarkers to monitor disease activity in response to therapeutic intervention. Fecal calprotectin (FC) and serum C-reactive protein (CRP) were identified as biomarkers ready for the regulatory qualification process. A number of exploratory biomarkers and potential panels of these biomarkers was also identified for additional development. Given the different factors involved in CD and disease progression, a combination of biomarkers, including inflammatory, tissue injury, genetic, and microbiome-associated biomarkers, will likely have the most utility. CONCLUSIONS: The primary focus of the Inflammatory Bowel Disease Regulatory Science Consortium will be development of exploratory biomarkers and the qualification of FC and CRP for IBD. The Inflammatory Bowel Disease Regulatory Science Consortium, focused on tools to support IBD drug development, will operate in the precompetitive space to share data, biological samples for biomarker testing, and assay information for novel biomarkers.
Authors: Flavia Bazzoni; Marzia Rossato; Marco Fabbri; Daniele Gaudiosi; Massimiliano Mirolo; Laura Mori; Nicola Tamassia; Alberto Mantovani; Marco A Cassatella; Massimo Locati Journal: Proc Natl Acad Sci U S A Date: 2009-03-16 Impact factor: 11.205
Authors: Abdul A Elkadri; Joanne M Stempak; Thomas D Walters; Simon Lal; Anne M Griffiths; A Hillary Steinhart; Mark S Silverberg Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: Nathaniel R West; Ahmed N Hegazy; Benjamin M J Owens; Samuel J Bullers; Bryan Linggi; Sofia Buonocore; Margherita Coccia; Dieter Görtz; Sébastien This; Krista Stockenhuber; Johanna Pott; Matthias Friedrich; Grigory Ryzhakov; Frédéric Baribaud; Carrie Brodmerkel; Constanze Cieluch; Nahid Rahman; Gerhard Müller-Newen; Raymond J Owens; Anja A Kühl; Kevin J Maloy; Scott E Plevy; Satish Keshav; Simon P L Travis; Fiona Powrie Journal: Nat Med Date: 2017-06-06 Impact factor: 53.440
Authors: Jeremy S Schaefer; Taraq Attumi; Antone R Opekun; Bincy Abraham; Jason Hou; Harold Shelby; David Y Graham; Charles Streckfus; John R Klein Journal: BMC Immunol Date: 2015-02-10 Impact factor: 3.615
Authors: Nicholas A Kennedy; Gareth-Rhys Jones; Nikolas Plevris; Rebecca Patenden; Ian D Arnott; Charlie W Lees Journal: Clin Gastroenterol Hepatol Date: 2019-02-14 Impact factor: 11.382
Authors: Joachim Høg Mortensen; Dovile Sinkeviciute; Tina Manon-Jensen; Viktor Domislović; Kathryn McCall; Christian S Thudium; Marko Brinar; Patrik Önnerfjord; Carl S Goodyear; Željko Krznarić; Morten Asser Karsdal; Anne-Christine Bay-Jensen Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020